EUVIMEDEUVIMED entdecken
Open Access

Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)

Md Maksudul Alam, Janmaris Marin Fermin, Mark Knackstedt, Mackenzie J Noonan, Taylor Powell, Landon Goodreau, Emily K Daniel, Xiaohua Rong, Tara Moore-Medlin, Alok R Khandelwal, Cherie-Ann O Nathan

Oncotarget · 02.02.2023 · 14 (1) · 85-95

DOI: 10.18632/oncotarget.28355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncotarget, online erschienen am 02.02.2023. Verfasst von Md Maksudul Alam und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, LSU-Health Sciences Center, Shreveport, LA 71103, USA. Hauptthemen laut MEDLINE: Everolimus, Head and Neck Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EverolimusHead and Neck NeoplasmsMiceAnimalsHumansSquamous Cell Carcinoma of Head and NeckLymphangiogenesisVascular Endothelial Growth Factor AMice, NudeTumor Suppressor Protein p53TOR Serine-Threonine KinasesNeovascularization, PathologicCell Line, TumorHypoxia-Inducible Factor 1, alpha SubunitSTAT3 Transcription Factor

Stichwörter der Autor:innen

HNSCCTP53 mutantangiogenesiseverolimusmTOR

Substanzen

EverolimusVascular Endothelial Growth Factor ATumor Suppressor Protein p53TOR Serine-Threonine KinasesHypoxia-Inducible Factor 1, alpha SubunitTP53 protein, humanSTAT3 protein, humanSTAT3 Transcription Factor

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, LSU-Health Sciences Center, Shreveport, LA 71103, USA.
  • School of Medicine, LSU-Health Sciences Center, Shreveport, LA 71103, USA.
  • Feist-Weiller Cancer Center, LSU-Health Sciences Center, Shreveport, LA 71103, USA.

Zitieren

APA

Alam, M. M., Fermin, J. M., Knackstedt, M., Noonan, M. J., Powell, T., Goodreau, L., Daniel, E. K., Rong, X., Moore-Medlin, T., Khandelwal, A. R., & Nathan, C. O. (2023). Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC). Oncotarget, 14(1), 85-95. https://doi.org/10.18632/oncotarget.28355

Vancouver

Alam MM, Fermin JM, Knackstedt M, Noonan MJ, Powell T, Goodreau L, et al. Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC). Oncotarget. 2023;14(1):85-95. doi:10.18632/oncotarget.28355

BibTeX
@article{Alam2023,
  author = {Alam, Md Maksudul and Fermin, Janmaris Marin and Knackstedt, Mark and Noonan, Mackenzie J and Powell, Taylor and Goodreau, Landon and Daniel, Emily K and Rong, Xiaohua and Moore-Medlin, Tara and Khandelwal, Alok R and Nathan, Cherie-Ann O},
  title = {Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)},
  journal = {Oncotarget},
  year = {2023},
  volume = {14},
  number = {1},
  pages = {85--95},
  doi = {10.18632/oncotarget.28355}
}
Kostenlos starten →